AKT1 and cancer: Several studies in different cancer types have already shown that inhibition by targeted therapy only for mTORC1 signaling is strongly associated with primary and acquired resistance to such treatment [38, 39], and this inhibition leads to the release of negative feedback and activation of Akt via PI3K, which is thought to attenuate the antitumor effect.